Foghorn will not advance FHD-909 to the trial's expansion phase and plans to cut about 40% of its staff, with $2.3 million in expected costs. It is shifting resources to other programs, but the lost trial step and Lilly work weigh more.
This removes a possible next step for one of Foghorn's partnered drugs and ends expected work with Lilly. The planned staff cut and cash costs add to the setback. Foghorn is shifting attention to other programs, but the filing reports no results showing they replace FHD-909's lost progress.
Eli Lilly and Foghorn will not take FHD-909 into the trial's expansion phase, and further work under their partnership is not expected. The filing gives no effect on Lilly's other work or finances, so it does not change the company outlook.
Follow Foghorn Therapeutics Inc. (FHTX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for FHTX